Tirzepatide Drugs Mounjaro and Zepbound Reduce Cardiovascular Risks in High-Risk Patients

GLP-1 weight loss medications containing tirzepatide—Mounjaro and Zepbound—significantly reduce cardiovascular risks in people with serious heart conditions, according to new research. Experts attribute these benefits to the drugs’ ability to aid weight loss and regulate blood sugar levels.

Patients using these medications should also maintain a healthy lifestyle, including daily exercise and a balanced diet, to support overall well-being.

Two studies presented at the SCAI 2026 Scientific Sessions CAIC-ACCI Summit in Montreal from April 23–25, 2026 indicate that GLP-1 drugs containing tirzepatide may lower heart-related risks for:

• Patients undergoing percutaneous coronary intervention (PCI)
• Individuals with obesity undergoing transcatheter aortic valve replacement (TAVR)

The findings have not yet been published in a peer-reviewed scientific journal.

Tirzepatide’s Role in Cardiovascular Health

Tirzepatide medications are typically prescribed to treat type 2 diabetes. A news release for the studies notes that tirzepatide’s ability to manage blood sugar and promote weight loss delivers “meaningful cardiovascular benefits.” While prior research has confirmed these advantages, their impact on patients undergoing interventional heart procedures has not been extensively studied.

Key findings include:

• A 62% lower risk of death among participants receiving tirzepatide who underwent PCI procedures
• Reduced rates of major adverse cardiovascular events, including acute myocardial infarction and stroke

“GLP-1 agonists represent an important evolution in cardiometabolic care. Clinicians already recognize the benefits of glycemic control and weight reduction, but we are now beginning to understand how these therapies can improve outcomes in patients undergoing transcatheter cardiovascular interventions.”

Expert Reactions and Future Research

Experts not involved in the studies support the findings, emphasizing tirzepatide’s broader cardiometabolic benefits.

“These findings are consistent with what we are seeing broadly—that medications like tirzepatide are not just weight loss drugs but have meaningful cardiometabolic benefits. We do need prospective studies to validate the findings from these analyses.”

Study Details: Tirzepatide’s Impact on PCI Patients

In the first study, researchers from John H. Stroger Jr. Hospital of Cook County, Chicago analyzed the TriNetX database. They identified adult participants with type 2 diabetes who received GLP-1 drugs containing tirzepatide or dulaglutide during their PCI procedure. The study did not compare tirzepatide with semaglutide-based medications like Ozempic or Wegovy.

The researchers reviewed medical records of 1,281 participants. One month after PCI, those using tirzepatide experienced lower rates of major adverse cardiovascular events, including:

• Acute myocardial infarction
• Stroke
• Heart failure